Archaebiotics: archaea as pharmabiotics for treating chronic disease in humans?

Show simple item record

dc.contributor.author Ben Hania, Wajdi
dc.contributor.author Ballet, Nathalie
dc.contributor.author Vandeckerkove, Pascal
dc.contributor.author Ollivier, Bernard
dc.contributor.author O'Toole, Paul W.
dc.contributor.author Brugère, Jean-François
dc.date.accessioned 2017-12-08T13:33:50Z
dc.date.available 2017-12-08T13:33:50Z
dc.date.issued 2017
dc.identifier.citation Ben Hania, W., Ballet, N., Vandeckerkove, P., Ollivier, B., O’Toole, P. W. and Brugère, J.-F. (2017) 'Archaebiotics: archaea as pharmabiotics for treating chronic disease in humans?', in Sghaier, H., Najjari, A. and Ghedira, K. (eds.) Archaea - New Biocatalysts, Novel Pharmaceuticals and Various Biotechnological Applications. Rijeka: InTech, pp. 41-62. doi: 10.5772/intechopen.69945 en
dc.identifier.startpage 41
dc.identifier.endpage 62
dc.identifier.uri http://hdl.handle.net/10468/5161
dc.identifier.doi 10.5772/intechopen.69945
dc.description.abstract Recent findings highlight the role of the human gut microbiota in various disorders. For example, atherosclerosis frequently seems to be the consequence of gut microbiota–derived metabolism of some dietary components. Pharmabiotics (i.e., live/dead microbes and microbe-derived substances) and probiotics (live microorganisms with a health benefit when administered in adequate amounts) are a means to counteract these deleterious effects. Among the latter, microbes now being used or, being currently developed, are bacteria and eukaryotes (yeasts), so omitting the third domain of life—the archaea, despite their unique properties that could be of great interest to human health. Here, we promote the idea that some specific archaea are potential next-generation probiotics. This is based on an innovative example of the bioremediation of a gut microbial metabolite. Indeed, besides the fact that they are archaea (i.e. originating from a domain of life from which no pathogens of humans/animals/plants are currently known), they are rationally selected based on (i) being naturally human-hosted, (ii) having a unique metabolism not performed by other human gut microbes, (iii) depleting a deleterious atherogenic compound generated by the human gut microbiota and (iv) generating a health inert gas.
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher InTech en
dc.rights © 2017, The Authors. Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. en
dc.subject Archaea
dc.subject Atherosclerosis
dc.subject Cardiovascular disease
dc.subject Methanogens
dc.subject Methanomassiliicoccales
dc.subject Next-generation probiotics
dc.subject Trimethylamine
dc.subject TMA
dc.subject Trimethylamine oxide
dc.subject TMAO
dc.subject Trimethylaminuria
dc.subject TMAU
dc.title Archaebiotics: archaea as pharmabiotics for treating chronic disease in humans? en
dc.type Book chapter en
dc.internal.availability Full text available en
dc.description.version Published Version en
dc.description.status Peer reviewed en
dc.identifier.journaltitle Archaea - New Biocatalysts, Novel Pharmaceuticals and Various Biotechnological Applications en
dc.internal.IRISemailaddress pwotoole@ucc.ie en


Files in this item

This item appears in the following Collection(s)

Show simple item record

This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement